AL

Nicox SAPAR Nicox Stock Report

Last reporting period 30 Jun, 2023

Updated 01 Nov, 2024

Last price

Market cap $B

0.012

Micro

Exchange

XPAR - Euronext Paris

ALCOX.PA Stock Analysis

AL

Uncovered

Nicox SA is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-54/100

Low score

Market cap $B

0.012

Dividend yield

Shares outstanding

50.011 B

Nicox SA is an ophthalmology company. The company is headquartered in Valbonne, Paca. The company is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The firm has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). The company has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.

View Section: Eyestock Rating